BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12934545)

  • 1. [Clinical application of FDG-PET for cancer diagnosis].
    Nakamoto Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Jul; 63(6):285-93. PubMed ID: 12934545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Esophageal cancer].
    Noboru O
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):265-9. PubMed ID: 12073632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
    Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
    Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography imaging in evaluation of cancer patients.
    Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
    Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical usefulness of FDG-PET in oncology].
    Sasaki M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
    Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
    J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical role of FDG PET in evaluation of cancer patients.
    Kostakoglu L; Agress H; Goldsmith SJ
    Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Present status of PET images: clinical FDG PET in oncology].
    Inoue T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of prostate cancer using FDG-PET].
    Kanamaru H; Oyama N; Akino H; Okada K
    Hinyokika Kiyo; 2000 Nov; 46(11):851-3. PubMed ID: 11193311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
    Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.